V8 Peptides — Engineered Performance
Research Library
PT-141 vs MT-2: Choosing a Melanocortin Reference Ligand
PT-141Comparison

PT-141 vs MT-2: Choosing a Melanocortin Reference Ligand

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

PT-141 or MT-2: which reference ligand fits an assay? Match the compound to the question: MT-2 is listed for MC1R and MC4R work and melanogenesis models, PT-141 for MC3R and MC4R work. Because they differ only at the C-terminus, the best design runs both on one plate with α-MSH, a vehicle and an antagonist, using full curves and matched molarity. Supplied for laboratory research use only.

A laboratory that studies melanocortin receptors eventually has to decide which agonist to use as its reference. PT-141 and MT-2 (melanotan II) are the two cyclic lactam heptapeptides that appear most often on that shortlist, and the decision is easy to get wrong because the two look interchangeable. This article approaches the pairing as an experimental-design problem: what question each compound is better placed to answer, how to build a paired experiment that separates the effect of the C-terminal group from everything else, and how much published context exists for each. It does not rank the compounds, and it reports no biological effects beyond what cited papers state.

Product facts come from the V8 pages: the PT-141 page describes a melanocortin MC4R agonist studied for central melanocortin signalling, MC3R and MC4R binding and functional assays, and neuroendocrine models. The MT-2 page describes a cyclic agonist studied for melanogenesis and MC-receptor signalling, with MC1R and MC4R receptor research, melanogenesis models and pigmentation-pathway studies listed as applications. Both are 10 mg lyophilized vials with a stated purity of at least 98% by HPLC, supplied for laboratory research use only. Chemical identity, including the one-terminal-group difference, is discussed in PT-141 vs melanotan II.

Start with the question, not the compound

The two product pages emphasize different receptor subtypes, which is a reasonable first filter. A pigment-cell project is built around MC1R, which is the subtype that controls melanogenesis, and the MT-2 page lists melanogenesis models and pigmentation-pathway studies. A project focused on central melanocortin signalling is built around MC3R and MC4R, the subtypes expressed in the central nervous system, which the PT-141 page names. A review of the receptor family notes that the five subtypes have different tissue distributions and signal through cyclic AMP (Yang, 2011), and a second review calls the central melanocortin pathway one of the best-characterized neuronal circuits involved in energy homeostasis (Cone, 2005). The table turns that into a first-pass decision aid. It is a planning heuristic, not a ruling about selectivity, which must be measured.

Study aimCell system typically usedStarting reference to considerWhy
Melanogenesis or pigment-pathway readoutCultured pigment cells (MC1R-driven)MT-2Product page lists melanogenesis models and MC1R work
MC4R binding or functional assayCells expressing recombinant MC4REither; run both as a pairBoth pages list MC4R activity; compare under identical conditions
MC3R-focused assayCells expressing recombinant MC3RPT-141 as one of a panelPT-141 page names MC3R and MC4R
Full subtype panel (MC1R–MC5R)Five single-receptor cell linesBoth, plus α-MSHSelectivity is a matrix question that needs every cell line

Context: how much literature stands behind each

A reference ligand is more useful the more its behaviour has been reported by others, because a lab can compare its curves with published ones. Melanotan II has the longer paper trail. A landmark 1997 study used cyclic melanocortin analogs, including the agonist MTII, to show that central administration of the agonist inhibited feeding in four models of hyperphagia and that cyclic analogs could be potent agonists or antagonists at the neural MC3 and MC4 receptors (Fan et al., 1997). A 2006 review of melanocortin analogs traces the lineage, describing melanotan I and melanotan II as patented analogs that were tested and PT-141 as a new analog of melanotan II (Hadley and Dorr, 2006).

Citing prior work cautiously matters. The 1997 paper concerns MTII in rodents with central administration, and its findings cannot be transferred to PT-141 or to cell-based assays by assertion. The right use of the older literature is to calibrate a new experiment: if a lab's MT-2 curve in a given cell line is in the range that others have seen, the system is behaving; if it is not, something about the assay needs attention. For PT-141 the comparable context is thinner in primary literature on receptor pharmacology, which argues for including MT-2 or α-MSH in the same plate as an internal bridge.

Build a paired experiment

The structural relationship makes a clean matched pair possible. Because the two compounds differ only at the C-terminus, any systematic difference between them in an otherwise identical experiment can be attributed to that group, subject to the caveat that lot purity and counterion may differ. The design rules below keep that attribution honest.

  • Run both on the same plate. Putting the two compounds, α-MSH and a vehicle control on one plate removes plate-to-plate drift as an explanation.
  • Match molarity, not just mass. The molar masses differ by about 0.1% (calculated from formulas C50H68N14O10 and C50H69N15O9), so equal masses are practically equimolar. Peptide content, which the label does not state, is the larger uncertainty.
  • Use full concentration-response curves with enough points to define top and bottom, so that potency and maximal response can be compared separately.
  • Include an antagonist. A known antagonist such as SHU9119, the ligand used in the MC4R crystal structure (Yu et al., 2020), shows that the signal runs through the receptor.
  • Control the buffer. Extracellular calcium raised the potency of α-MSH at MC4R by 600-fold in that structural study (Yu et al., 2020), so record and fix divalent cation content.
  • Repeat with an independent stock. Prepare each compound from a fresh vial or an independently weighed portion to separate compound behaviour from preparation error.

Stock arithmetic is the same for both: concentration equals mass divided by the product of molar mass and diluent volume. The reconstitution calculator performs it, and peptide reconstitution volume calculations explains each term.

Readout selection and what each readout can resolve

Potency is not a property of the molecule alone; it depends on the readout. Cyclic AMP accumulation is the canonical downstream signal of melanocortin receptors (Yang, 2011). A cAMP assay is fast and widely used, but it amplifies weak signals, so a partial agonist can look full. A competition-binding assay measures affinity without function. Structural work has also described G-protein-independent coupling of MC4R to the ion channel Kir7.1 (Yu et al., 2020), meaning that two ligands with the same cAMP behaviour could differ in channel coupling. A thorough comparison of PT-141 and MT-2 would therefore report binding, cAMP and, where feasible, a second pathway.

ReadoutWhat a difference between PT-141 and MT-2 would indicateWhat it would not indicate
Competition bindingDifferent affinity for the receptorDifferent efficacy
cAMP accumulationDifferent Gs-coupled potency or maximal responseDifferent signalling bias
Channel or second-pathway readoutPossible bias between pathwaysAnything about intact organisms
Selectivity panel across MC1R–MC5RA different subtype profileWhich profile is preferable for any purpose

Reporting standards that make a comparison reusable

Two papers that both say "PT-141 was more selective than MT-2" are not comparable unless they say how. A reusable report names the receptor species and construct, the cell line and passage range, the expression level where known, the readout and incubation time, the buffer composition including calcium, the reference ligands, the number of independent experiments, and the lot numbers of each compound. Documentation for the V8 material is described on the COA page; certificate status is stated per product, and where a certificate is marked as in progress the identity and purity of that lot should be regarded as unverified in the record. Handling guidance applies equally to both vials: store at 2–8 °C, or at −20 °C long term, and protect from heat, moisture and light, as the product pages state; see storing research peptides.

Quality checks specific to each compound are in PT-141 purity testing and melanotan II purity testing, and the mechanism of the parent family is covered in the melanotan II research overview.

Common design errors

Four errors recur. Comparing the two compounds on different days with different cell passages; using a single concentration and calling it potency; handling a published selectivity ratio from one cell line as a property of the molecule; and omitting an identity check even though the compounds are one dalton apart. A study that avoids these four is already better than much of the casual literature. For ordering context, see where to buy melanotan II and the shop page.

Frequently asked questions

Which should I use as a melanocortin reference ligand, PT-141 or MT-2?

It depends on the question. MT-2 has the longer published history and is listed for MC1R and MC4R work and melanogenesis models; PT-141 is listed for MC3R and MC4R work. For a comparison, run both on one plate with α-MSH.

How are PT-141 and MT-2 related?

They share the same cyclic lactam scaffold and sequence except at the C-terminus, where PT-141 has a free acid and MT-2 an amide. A review of melanocortin analogs lists PT-141 as a new analog of melanotan II.

Why is a matched pair useful?

Because only one group differs, any consistent difference in an otherwise identical experiment can be attributed to it, provided lot purity and counterion are also considered.

Do equal masses of the two compounds give equal molar concentrations?

Nearly: the calculated molar masses differ by about 0.1%. The larger uncertainty is peptide content, which the label does not state.

What controls should a receptor assay include?

α-MSH as a reference agonist, a vehicle control, an antagonist such as SHU9119 and, ideally, parental cells that lack the receptor.

Does calcium affect the results?

In the MC4R structural study, extracellular calcium increased the potency of α-MSH by 600-fold (Yu et al., 2020). Record and fix cation content in the buffer.

Are rodent studies on melanotan II relevant to my cell assay?

They provide context, not calibration for PT-141. The 1997 feeding studies used central administration of MTII in animals (Fan et al., 1997) and answer a different question from a cell-based binding or cAMP assay.

Can I use a purity percentage to confirm which compound I have?

No. Both pages state a purity of at least 98% by HPLC, which says nothing about acid versus amide. Identity requires a method that resolves a one-dalton difference.

How should both compounds be stored?

Each product page states 2–8 °C, −20 °C for long-term storage, and protection from heat, moisture and light.

Are these compounds intended for human or animal use?

No. Both are supplied strictly for laboratory research use only and are not intended for human or animal consumption.

Related reading: PT-141 Reconstitution for In Vitro Assays, PT-141 in Receptor Binding and cAMP Assays, PT-141 and the Melanocortin Receptors: Assay Guide.

References

  1. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0
  2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
  3. Yang Y. Structure, function and regulation of the melanocortin receptors. Eur J Pharmacol. 2011;660(1):125-130. doi:10.1016/j.ejphar.2010.12.020
  4. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571-578. doi:10.1038/nn1455
  5. Yu J, Gimenez LE, Hernandez CC, et al. Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding. Science. 2020;368(6489):428-433. doi:10.1126/science.aaz8995

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.